Thank you for subscribing!
Finfeed Archived Dec 16, 2020
Neurotech International Limited (ASX:NTI) has commenced a stage 1 clinical product formulation and development studies and anticipates entering clinical trials in the March quarter next year.
Get expert stock analysis direct in your inbox
Join Our Mailing List